2022-08-16 10:00:00 CEST

2022-08-16 10:00:02 CEST


REGULATED INFORMATION

English
Optomed Oyj - Changes in the rights attached to the classes of shares or securities

Optomed's Board has resolved upon a new option plan


Optomed PlcStock Exchange Release16 August 2022 at 11.00, Helsinki

Optomed's Board has resolved upon a new option plan

Optomed's board of directors has resolved upon a new option plan. The resolution
is based on the authorization given by the general meeting of 10 May 2022.

Option plan 2022A:

The total number of options is 250,000 and each option entitled to one share of
the company. The options are offered to certain key employees. The purpose of
the plan is to retain and incentifize key employees.  The subscription price is
EUR 4.17 corresponding the closing price of 12 August 2022, and the subscription
period is 1 January 2026 - 31 December 2027.

The theoretical market value of one option under the plan 2022A is approximately
EUR 1.771 per stock option and the theoretical total market value of the plan
2022A is approximately 442,750.00 euros in total. The theoretical market value
of a stock option has been calculated by using the Black & Scholes stock option
pricing model with the following input factors: share price EUR 4.04 euros,
subscription price EUR 4.17, risk free interest rate 0.0%, validity of stock
options approximately 3.4 years and volatility 64.07%.

The complete terms and conditions of the option plan 2022A are attached to this
release.

Optomed Plc

Further enquiries

Sakari Knuutti, CFO, Optomed Plc, sakari.knuutti@optomed.com

Optomed in Brief

Optomed is a Finnish medical technology company and one of the leading providers
of handheld fundus cameras. Optomed combines handheld cameras with software and
artificial intelligence with the aim to transform the diagnostic process of
blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its
business Optomed focuses on eye-screening devices and software solutions related
R&D in Finland and sales through different channels in over 60 countries. The
company has an extensive portfolio of 55 international patents protecting the
technology.

www.optomed.com



08161083.pdf